

BIO-TECHNE CORP.

ISIN: US09073M1045 WKN: 09073M104 Asset Class: Stock

Company

2024/05/17 22:00:00

biotechne®

Price

83.81

USD

Difference

1.16%(0.97)



Contact Details

BIO-TECHNE CORP.

Tel: +1-612-379-8854

--

Fax: +1-612-656-4400

614 McKinley Place North
East

Web: <http://www.biotechne.com>

55413-2610 Minneapolis

E-mail: info@bio-techne.com

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Financial figures, Fiscal year: from 01.07. to 30.06.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	621,482,000		605,556,000		510,606,000	
Common stock capital		1,576,000		392,000		390,000
Fixed assets	2,112,233,000		1,765,472,000		1,839,234,000	
Equity capital of a company		1,966,516,000		1,701,011,000		1,571,234,000
Cash and cash equivalents	180,571,000		172,567,000		199,091,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		128,509,000		176,018,000		152,284,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		638,690,000		493,999,000		626,322,000
Different income		-		-		-
Other liabilities		10,919,000		17,239,000		49,862,000
Total assets	2,733,715,000	2,733,715,000	2,371,028,000	2,371,028,000	2,349,840,000	2,349,840,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	3,050	3,000	2,600
Equity ratio	71.94%	71.71%	67.22%
Debt-equity ratio	39.01%	39.45%	48.77%

Others

	2023	2022	2021
Tax Expense Rate	15.71%	12.70%	5.80%

BIO-TECHNE CORP.

ISIN: US09073M1045 WKN: 09073M104 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	1,136,702,000	1,105,599,000	931,032,000
Net income	285,193,000	271,930,000	140,324,000
EBIT	321,363,773	292,283,555	156,359,437
Operating income before taxes	338,659,000	301,386,000	148,175,000
Cash Flow	254,393,000	325,272,000	352,164,000
Net interest income	-11,258,000	-16,867,000	-22,077,000
Research and development expenses	92,493,000	87,140,000	70,603,000
Income taxes	53,217,000	38,287,000	8,590,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	342,278	338,461	328,869

Board of Directors

Members of Management Board

Robert Baumgartner	Chairman of Board of Directors
Alpna Seth	Member of Board of Directors
Joseph Keegan	Member of Board of Directors
Judith Klimovsky	Member of Board of Directors
Randolph Steer	Member of Board of Directors
Roeland Nusse	Member of Board of Directors
Rupert Vessey	Member of Board of Directors
John Higgins	Member of Board of Directors
Julie Bushman	Member of Board of Directors
Charles Kummeth	Chairman of Managing Board
Brenda S. Everson	Member of Executive Committee
Jim Hippel	Member of Executive Committee
Kevin Smyth	Member of Executive Committee